430
Participants
Start Date
October 18, 2024
Primary Completion Date
January 20, 2028
Study Completion Date
January 20, 2028
AZD0022
AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.
Cetuximab
Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands
RECRUITING
Research Site, Edegem
RECRUITING
Research Site, Melbourne
RECRUITING
Research Site, Leuven
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, New York
NOT_YET_RECRUITING
Research Site, Bangkok
NOT_YET_RECRUITING
Research Site, Bangkok
RECRUITING
Research Site, Milan
RECRUITING
Research Site, Fairfax
RECRUITING
Research Site, Madrid
RECRUITING
Research Site, Madrid
NOT_YET_RECRUITING
Research Site, Istanbul
NOT_YET_RECRUITING
Research Site, Verona
RECRUITING
Research Site, Nashville
RECRUITING
Research Site, Valencia
RECRUITING
Research Site, San Antonio
NOT_YET_RECRUITING
Research Site, Napoli
RECRUITING
Research Site, Duarte
NOT_YET_RECRUITING
Research Site, Beijing
NOT_YET_RECRUITING
Research Site, Zhengzhou
RECRUITING
Research Site, Chengdu
NOT_YET_RECRUITING
Research Site, Hong Kong
RECRUITING
Research Site, Stanford
RECRUITING
Research Site, Edmonton
RECRUITING
Research Site, Toronto
RECRUITING
Research Site, Montreal
RECRUITING
Research Site, Kashiwa
RECRUITING
Research Site, Tokyo
RECRUITING
Research Site, Amsterdam
RECRUITING
Research Site, Gdansk
RECRUITING
Research Site, Lodz
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Barcelona
RECRUITING
Research Site, L'Hospitalet de Llobregat
NOT_YET_RECRUITING
Research Site, Ankara
NOT_YET_RECRUITING
Research Site, Cambridge
NOT_YET_RECRUITING
Research Site, Manchester
NOT_YET_RECRUITING
Research Site, Newcastle upon Tyne
Lead Sponsor
AstraZeneca
INDUSTRY